Suppr超能文献

NEK2在肿瘤发生和肿瘤进展中的作用。

Role of NEK2 in tumorigenesis and tumor progression.

作者信息

Xia Jiliang, Zhao Hongyan, Edmondson Jacob L, Koss Brian, Zhan Fenghuang

机构信息

Hunan Engineering Research Center for Early Diagnosis and Treatment of Liver Cancer, Cancer Research Institute, Hengyang Medical School, University of South China, Changshengxi Road 28, Hengyang, 421001, Hunan, China.

Hunan Engineering Research Center for Early Diagnosis and Treatment of Liver Cancer, Cancer Research Institute, Hengyang Medical School, University of South China, Changshengxi Road 28, Hengyang, 421001, Hunan, China.

出版信息

Trends Mol Med. 2025 Jan;31(1):79-93. doi: 10.1016/j.molmed.2024.07.013. Epub 2024 Aug 24.

Abstract

Never in mitosis A (NIMA)-related kinase 2 (NEK2) is a serine/threonine kinase found in the nucleus and cytoplasm throughout the cell cycle. NEK2 is overexpressed in many cancers and is a biomarker of poor prognosis. Factors contributing to NEK2 elevation in cancer cells include oncogenic transcription factors, decreased ubiquitination, DNA methylation, and the circular RNA (circRNA)/long noncoding RNA (lncRNA)-miRNA axis. NEK2 overexpression produces chromosomal instability and aneuploidy, thereby enhancing cancer progression and suppressing antitumor immunity, which highlights the prominence of NEK2 in tumorigenesis and tumor progression. Small-molecule inhibitors targeting NEK2 have demonstrated promising therapeutic potential in vitro and in vivo across various cancer types. This review outlines the regulatory mechanisms of NEK2 expression, emphasizes its functional roles in cancer initiation and progression, and highlights the anticancer properties of NEK2 inhibitors.

摘要

有丝分裂A期相关激酶2(NEK2)是一种丝氨酸/苏氨酸激酶,在整个细胞周期中存在于细胞核和细胞质中。NEK2在许多癌症中过度表达,是预后不良的生物标志物。导致癌细胞中NEK2升高的因素包括致癌转录因子、泛素化减少、DNA甲基化以及环状RNA(circRNA)/长链非编码RNA(lncRNA)-微小RNA(miRNA)轴。NEK2的过度表达会导致染色体不稳定和非整倍体,从而促进癌症进展并抑制抗肿瘤免疫,这突出了NEK2在肿瘤发生和肿瘤进展中的重要性。靶向NEK2的小分子抑制剂在体外和体内对各种癌症类型均显示出有前景的治疗潜力。本综述概述了NEK2表达的调控机制,强调了其在癌症起始和进展中的功能作用,并突出了NEK2抑制剂的抗癌特性。

相似文献

1
Role of NEK2 in tumorigenesis and tumor progression.
Trends Mol Med. 2025 Jan;31(1):79-93. doi: 10.1016/j.molmed.2024.07.013. Epub 2024 Aug 24.
3
PLK4: a promising target for cancer therapy.
J Cancer Res Clin Oncol. 2019 Oct;145(10):2413-2422. doi: 10.1007/s00432-019-02994-0. Epub 2019 Sep 6.
6
The role of mir-151a-5p in tumorigenesis; A systematic review.
Pathol Res Pract. 2023 Sep;249:154576. doi: 10.1016/j.prp.2023.154576. Epub 2023 Jun 1.
7
Targeting NEK2 as a promising therapeutic approach for cancer treatment.
Cell Cycle. 2016;15(7):895-907. doi: 10.1080/15384101.2016.1152430.
9
YAP/TAZ: An epitome of tumorigenesis.
Cancer Lett. 2025 Aug 10;625:217806. doi: 10.1016/j.canlet.2025.217806. Epub 2025 May 15.
10
Serine-Arginine Protein Kinase 1 (SRPK1): a systematic review of its multimodal role in oncogenesis.
Mol Cell Biochem. 2022 Oct;477(10):2451-2467. doi: 10.1007/s11010-022-04456-7. Epub 2022 May 18.

引用本文的文献

3
Deciphering the multifaceted role of circular RNA in aging: from molecular mechanisms to therapeutic potentials.
Noncoding RNA Res. 2025 May 30;14:129-144. doi: 10.1016/j.ncrna.2025.05.015. eCollection 2025 Oct.
4
Bioinformatics analysis across pan-cancer and experimental validation in hepatocellular carcinoma revealed the oncogenic role of SF3B6.
Front Pharmacol. 2025 Apr 28;16:1516534. doi: 10.3389/fphar.2025.1516534. eCollection 2025.
5
NEK2 inhibition alleviates lipopolysaccharide-induced endothelial injury.
ASPET Discov. 2025;1. doi: 10.1016/j.aspetd.2025.100002. Epub 2025 Mar 18.
8
NEK kinases in cell cycle regulation, DNA damage response, and cancer progression.
Tissue Cell. 2025 Jun;94:102811. doi: 10.1016/j.tice.2025.102811. Epub 2025 Feb 28.

本文引用的文献

1
Function of NEK2 in clear cell renal cell carcinoma and its effect on the tumor microenvironment.
Medicine (Baltimore). 2024 May 17;103(20):e37939. doi: 10.1097/MD.0000000000037939.
2
NEK2 promotes the migration, invasion, proliferation of ESCC and mediates ESCC immunotherapy.
Heliyon. 2024 Apr 23;10(9):e29682. doi: 10.1016/j.heliyon.2024.e29682. eCollection 2024 May 15.
3
Retinoblastoma Origins and Destinations.
N Engl J Med. 2024 Apr 18;390(15):1408-1419. doi: 10.1056/NEJMra1803083.
4
Inhibition of NEK2 Promotes Chemosensitivity and Reduces KSHV-positive Primary Effusion Lymphoma Burden.
Cancer Res Commun. 2024 Apr 9;4(4):1024-1040. doi: 10.1158/2767-9764.CRC-23-0430.
5
Targeting and engineering long non-coding RNAs for cancer therapy.
Nat Rev Genet. 2024 Aug;25(8):578-595. doi: 10.1038/s41576-024-00693-2. Epub 2024 Feb 29.
6
Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers.
Oncogene. 2024 Feb;43(8):578-593. doi: 10.1038/s41388-023-02926-w. Epub 2024 Jan 5.
7
Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma.
Cell Metab. 2024 Jan 2;36(1):159-175.e8. doi: 10.1016/j.cmet.2023.11.019. Epub 2023 Dec 18.
8
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies.
Signal Transduct Target Ther. 2023 Dec 18;8(1):455. doi: 10.1038/s41392-023-01705-z.
9
Breaking barriers: NEK2 inhibition shines in multiple myeloma treatment.
Cell Rep Med. 2023 Oct 17;4(10):101237. doi: 10.1016/j.xcrm.2023.101237.
10
Cancer cell-intrinsic mechanisms driving acquired immune tolerance.
Immunity. 2023 Oct 10;56(10):2270-2295. doi: 10.1016/j.immuni.2023.09.004.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验